Overview
TSH Receptor Antibody, commonly known as TRAb, is an autoantibody directed against the thyroid-stimulating hormone receptor on thyroid follicular cells. It is a key marker in autoimmune thyroid diseases and plays a central role in the pathogenesis of Graves’ disease. TRAb antibodies bind to the TSH receptor and are defined by their biological action.
Activating antibodies stimulate the receptor, leading to increased thyroid hormone production and hyperthyroidism, while blocking antibodies inhibit receptor function and may contribute to hypothyroidism. TRAb testing is highly sensitive and specific for Graves’ disease, with positivity seen in the majority of affected patients.
Symptoms
TSH Receptor Antibody positivity is associated with symptoms of thyroid hormone imbalance rather than symptoms caused by the antibody itself. Patients with stimulating TRAb commonly present with features of hyperthyroidism such as weight loss, heat intolerance, palpitations, tremors, excessive sweating, anxiety, increased appetite, and fatigue. Eye symptoms, including proptosis, eye irritation, or unilateral orbitopathy, may also be present in Graves’ disease. In cases where blocking antibodies predominate, symptoms of hypothyroidism such as weight gain, cold intolerance, lethargy, dry skin, and constipation may be observed.
Causes
TRAb production is caused by autoimmune dysregulation targeting the TSH receptor. In Graves’ disease, stimulating TRAb leads to continuous activation of the thyroid gland, resulting in autoimmune thyrotoxicosis. Blocking TRAb may be seen in autoimmune thyroiditis and can suppress thyroid hormone production.
TRAb may also be detected in patients undergoing immune reconstitution, during pregnancy, or in individuals previously treated with radioactive iodine or thyroid surgery. A small percentage of healthy individuals may show low-level TRAb positivity.
Risk Factors
Risk factors for TRAb positivity include autoimmune thyroid disease, family history of thyroid disorders, female gender, and pregnancy. Patients with Graves’ disease, thyrotoxicosis of unclear origin, or euthyroid orbitopathy are at increased risk.
Pregnant women with a history of Graves’ disease, previous radioactive iodine therapy, thyroid surgery, or a prior child with neonatal thyroid dysfunction have a higher likelihood of clinically significant TRAb levels. Ongoing treatment with anti-thyroid drugs also influences antibody levels.
Prevention
Prevention focuses on early identification and monitoring rather than the prevention of antibody formation itself. Timely TRAb testing helps differentiate Graves’ disease from other causes of hyperthyroidism and supports appropriate treatment selection.
Monitoring TRAb levels during treatment helps assess disease activity and risk of relapse. In pregnancy, screening and follow-up reduce the risk of fetal and neonatal thyroid dysfunction. Early diagnosis, regular monitoring, and appropriate management help prevent complications related to uncontrolled thyroid disease.
